Compare · AZN vs GRVI
AZN vs GRVI
Side-by-side comparison of AstraZeneca PLC (AZN) and Grove Inc. (GRVI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and GRVI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 3889.6x GRVI ($67.6M).
- AZN has hit the wire 15 times in the past 4 weeks while GRVI has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 0 for GRVI).
- Company
- AstraZeneca PLC
- Grove Inc.
- Price
- $166.71-1.74%
- $4.63+0.87%
- Market cap
- $263.10B
- $67.6M
- 1M return
- -3.39%
- -
- 1Y return
- -11.46%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Grove Inc.
Grove, Inc., through its subsidiaries, engages in developing, producing, marketing, and selling raw materials, white label products, and end consumer products containing the industrial hemp plant extract, cannabidiol. The company serves consumer markets, including the botanical, beauty care, pet care, and functional food sectors. It also operates annual tradeshow related to the CBD industry in the United States. Grove, Inc. was incorporated in 2018 and is headquartered in Henderson, Nevada.
Latest AZN
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Latest GRVI
- SEC Form 4: Marshall Allan bought $63,909 worth of shares (17,303 units at $3.69), increasing direct ownership by 0.68% to 2,575,081 units
- Grove Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4: Marshall Allan bought $49,320 worth of shares (12,000 units at $4.11), increasing direct ownership by 0.47% to 2,557,778 units
- SEC Form 4: Marshall Allan bought $73,161 worth of shares (18,475 units at $3.96), increasing direct ownership by 0.73% to 2,545,778 units
- SEC Form EFFECT filed by Grove Inc.
- Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form POS AM filed by Grove Inc.
- Grove Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Salkind Gene